Mr. Costa held many roles at Novartis, including President and Chief Executive Officer of Novartis U.S. Corporation, Head of the Americas, and President and Chief Executive Officer of Novartis Pharmaceutical Corporation. Prior to joining Novartis, Mr. Costa worked at Johnson & Johnson for 30 years, where he served as President of Janssen Pharmaceutica, Executive Vice President, Global Franchise Development, and was a member of Johnson & Johnson's Group Operating Committee. Mr. Costa has held various sales and marketing positions and has more than 20 years of general management experience, having launched 10 pharmaceutical products in various therapeutic areas in the U.S. market. Mr. Costa earned his M.B.A. from
In addition to the new nominees, the Company is nominating current directors Adrian Adams, Steven R. Altman, Teresa Beck, Daniel M. Bradbury, Joseph C. Cook, Jr., Karin Eastham, James R. Gavin III, M.D., Ph.D., Jay S. Skyler, M.D., Joseph P. Sullivan and James N. Wilson for re-election. With their broad range of expertise, diverse perspectives, and in-depth knowledge of Amylin's business, these directors will continue to serve the best interests of all Amylin stockholders.
"We are confident that this is the right slate to represent the interests of all our stockholders and to ensure that Amylin is well positioned for sustainable long-term success," said James N. Wilson, Lead Independent Director of Amylin's Board. "We engaged in a thorough and comprehensive process to assemble this slate. After considerable evaluation, we identified these nominees as those most qualified to serve the needs of the Company and maximize value for all Amylin stockholders."
Two current directors, Howard E. (Ted) Greene, Jr. and Ginger L. Graham, will not stan
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved